2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2530 Allogeneic blood or marrow transplantation with post-transplant cyclophosphamide for large B-cell lymphoma in the CAR-T era

Frederick Ian Lemaistre, MD, MPH, Ravi Varadhan, PhD2, Tania Jain, MBBS3, Jorge Florindez, MD4, Suman Paul, PhD, MBBS5, Ephraim Fuchs, MD6, Javier Bolanos-Meade, MD7, Philip Imus, MD8, Christian Burris Gocke, MD, PhD9, Jonathan Allen Webster, MD10, Carol Huff, MD11, Syed Abbas Ali, MBBS12, Lukasz P. Gondek, MD, PhD13, Gabriel Ghiaur, MD, PhD14, William Brian Dalton, MD, PhD15, Theodoros Karantanos, MD, PhD16, Gabrielle T. Prince, MD17, Mark J. Levis I, MD PhD18, Ivana Gojo, MD19, Amy DeZern, MD, MHS20, Nina Wagner-Johnston, MD21, Richard Ambinder, MD, PhD22, Richard John Jones, MD23, Cole H Sterling, MD24
1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
2 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
3 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
4 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
5 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
6 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
7 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
8 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
9 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
10 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
11 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
12 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
13 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
14 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
15 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
16 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
17 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
18 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
19 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
20 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
21 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
22 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
23 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
24 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States

Introduction:  While outcomes in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) have improved significantly with the advent of chimeric antigen receptor T-cell therapy (CAR-T) and bispecific antibodies (BsAbs), most patients ultimately relapse and die from their disease. Allogeneic blood or marrow transplantation (alloBMT) remains a potentially curative option, which has declined in use for LBCL with the approval of CAR-T. We performed a retrospective, single-center analysis of patients with R/R LBCL treated with alloBMT using non-myeloablative (NMA) or reduced intensity conditioning (RIC) and post-transplant cyclophosphamide (PTCy) to evaluate outcomes in the era of CAR-T and BsAbs.

Methods: We queried all patients >18 years old with LBCL who underwent alloBMT from January 1st, 2017 through December 31st, 2025 at the Johns Hopkins Hospital. All patients received fludarabine, cyclophosphamide, and 2 gray (Gy) total body irradiation (TBI), aside from 7 patients receiving 4 Gy.  Graft-versus-host disease (GVHD) prophylaxis consisted of PTCy, mycophenolate mofetil, and either tacrolimus or sirolimus. The primary endpoint was overall survival (OS). Secondary endpoints were relapse-free survival (RFS), relapse, non-relapse mortality (NRM), grade III-IV acute GVHD (aGVHD), moderate or severe chronic GVHD (cGVHD), GVHD-free, relapse free survival (GRFS), and count recovery. Time-to-event outcomes were estimated by Kaplan Meier methods, and outcomes with competing risk were estimated using cumulative incidence functions with Fine-Gray models for regression analyses.  Multivariable (MVA) Cox regression evaluated association of variables including age, donor type, graft, prior therapies, disease response, and receipt of maintenance therapy with investigated outcomes.

Results: We identified 127 patients with a median follow up of 53.7 months (95% CI: 45- 61.5) by reverse Kaplan-Meier method. Median patient age was 60 years (range, 26-77). Histologies included diffuse large B-cell lymphoma (DLBCL) in 107 (84.3%), high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement in 16 (12.6%), and primary mediastinal LBCL in 4 (3.1%) patients. Among those with DLBCL, 44 were germinal center subtype, 54 were non-germinal center subtype, and 9 were unknown cell-of-origin subtype. A total of 70 patients (55%) had transformed disease, including 13 cases of Richter’s transformation (10.2%). The median prior lines of therapy was 2 (range, 1-5), with 20 patients (15%) receiving prior CAR-T, 14 (11%) receiving prior antibody-drug conjugate, 9 receiving prior immune checkpoint inhibitor (6.8%), 8 (6.1%) receiving prior BsAbs, and 6 (4.5%) receiving prior autologous stem cell transplant. All patients were in complete (61%) or partial (39%) remission at the time of alloBMT. Donor type was haploidentical in 78%, full match in 11%, and mismatch unrelated in 11%, with 90 patients receiving bone marrow (71%) and 37 receiving peripheral blood (29%). A total of 25 patients (19%) received post-transplant maintenance: 12 (9.4%) with a BSA, 8 (6.3%) with a monoclonal antibody, and 5 (3.9%) with other therapies. At 1, 3, and 5 years after alloBMT, respectively, OS was 72.6% (65.1-80.9%), 64.1% (55.9-73.4%), and 59.8% (51.1-70%). RFS was 59.2% (51.2-68.5%), 54.2% (46.0-63.9%), and 50.4% (41.8-60.7%). NRM was 10.4% (5.8-16.5%), 12.5% (7.3-19.1%), and 14.1% (8.2- 21.5%). Relapse was 29.6% (21.8-37.7%), 31.6% (23.5-40.0%), and 33.8% (25.4-42.4%). Grade III-IV aGVHD at day +100 was 7.1% (3.5-12.4%). Moderate/severe cGVHD was 7.9% (4.0-13.5%) and 8.8% (4.6-14.6%) at 12 and 24 months, respectively. GRFS at 1, 3, and 5 years was 47.9% (39.9-57.4%), 41.1% (33.2-51.0%), and 37.4% (29.4-47.6%), respectively. Platelet and neutrophil recovery on day +28 and +60 occurred in 51% (42%-60%) and 94% (88%-97%) and 95% (89%-98%) and 98% (92%-99%), respectively. In MVA, only age by decade was associated with an inferior OS (HR 1.33, 1.03-1.72 p = 0.029), without other significant predictors of OS, RFS, GRFS, relapse, or NRM.

Conclusions: In this single-center retrospective analysis of 127 patients undergoing alloBMT with PTCy for LBCL, long-term outcomes in the era of CAR-T are promising with 5-year OS and RFS of 59.8% and 50.4%, respectively in a heavily pretreated disease cohort with durable remissions and low NRM.  This data supports the safety and efficacy of alloBMT with PTCy for LBCL, an underutilized complementary treatment in the CAR-T era.
Frederick Ian Lemaistre, MD, MPH: No relevant conflicts of interest to declare.